SCHEMBL6086708

SCHEMBL6086708

NC(=O)CC1OC(=C2C(=O)Nc3ccccc32)c2ccccc21

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B10 Q99714 2/20 0.46
ALDH1A1 P00352 4/20 0.39
IDO1 P14902 4/20 0.38
TDO2 P48775 1/20 0.38
LMNA P02545 4/20 0.37
KDM4E B2RXH2 2/20 0.37
MAPT P10636 3/20 0.37
MEN1 O00255 1/20 0.37
CYP1A2 P05177 1/20 0.37
CYP3A4 P08684 1/20 0.37
CYP2C9 P11712 1/20 0.37
HPGD P15428 1/20 0.37
CYP2C19 P33261 1/20 0.37
KMT2A Q03164 1/20 0.37
RECQL P46063 1/20 0.37
PKM P14618 1/20 0.37
MAPK1 P28482 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37
LRRK2 Q5S007 3/20 0.36
MAOA P21397 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6086705 1.00 HSD17B10 (0.46) HSD17B10ALDH1A1IDO1TDO2LMNA
SCHEMBL14725098 0.90 HSD17B10 (0.36) HSD17B10ALDH1A1IDO1TDO2LMNA
SCHEMBL6087504 0.90 APEX1 (0.43) HSD17B10ALDH1A1IDO1TDO2LMNA
SCHEMBL6086671 0.90 APEX1 (0.43) HSD17B10ALDH1A1IDO1TDO2LMNA
SCHEMBL6086673 0.90 APEX1 (0.43) HSD17B10ALDH1A1IDO1TDO2LMNA
SCHEMBL14715578 0.88 ALDH1A1 (0.38) HSD17B10ALDH1A1IDO1TDO2LMNA
SCHEMBL14715577 0.88 ALDH1A1 (0.38) HSD17B10ALDH1A1IDO1TDO2LMNA
SCHEMBL14725113 0.86 LRRK2 (0.36) HSD17B10ALDH1A1IDO1TDO2LMNA
SCHEMBL6087420 0.86 TAOK1 (0.35) HSD17B10ALDH1A1IDO1TDO2LMNA
SCHEMBL6087424 0.86 TAOK1 (0.35) HSD17B10ALDH1A1IDO1TDO2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1490356-B1 (3Z)-3-(3-HYDRO-ISOBENZOFURAN-1-YLIDENE)-1,3-DIHYDRO-2H-INDOL-2-ONES AS KINASE INHIBITORS ALLERGAN INC (US) 2013-02-27 EP disclosed
US-7060844-B2 (3Z)-3-(2,3-dihydro-1H-inden-1-ylidene)-1,3-dihydro-2H-indol-2-ones as kinase inhibitors ALLERGAN, INC. (US) 2006-06-13 US disclosed
US-20060004084-A1 (3Z)-3-(2,3-dihydro-1H-inden-1-ylidene)-1,3-dihydro-2H-indol-2-ones as kinase inhibitors ALLERGAN, INC. 2006-01-05 US disclosed
EP-1490356-A1 (3Z)-3-(3-HYDRO-ISOBENZOFURAN-1-YLIDENE)-1,3-DIHYDRO-2H-INDOL-2-ONES AS KINASE INHIBITORS Allergan, Inc. (US) 2004-12-29 EP disclosed
US-20040019098-A1 (3Z)-3-(2,3-dihydro-1H-inden-1-ylidene)-1,3-dihydro-2H-indol-2-ones as kinase inhibitors ALLERGAN, INC. 2004-01-29 US disclosed
WO-2003084951-A1 (3Z) -3-(3-HYDRO-ISOBENZOFURAN-1-YLIDENE)-1, 3-DIHYDRO-2H-INDOL-2-ONES AS KINASE INHIBITORS ALLERGAN, INC. (US) 2003-10-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060004084-A1 (3Z)-3-(2,3-dihydro-1H-inden-1-ylidene)-1,3-dihydro-2H-indol-2-ones as kinase inhibitors CDK2, ERBB2, MAP3K3 HSD17B10 3034/4885ALDH1A1 1528/4885IDO1 213/4885
US-20040019098-A1 (3Z)-3-(2,3-dihydro-1H-inden-1-ylidene)-1,3-dihydro-2H-indol-2-ones as kinase inhibitors CDK2, ERBB2, MAP3K3 HSD17B10 3073/4885ALDH1A1 1606/4885IDO1 235/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.